{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:35:22Z","timestamp":1790224522353,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/cji.0000000000000088","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T20:02:58Z","timestamp":1439323378000},"page":"299-305","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL"],"prefix":"10.1097","volume":"38","author":[{"given":"Holly J.","family":"Meany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita L.","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doojduen","family":"Villaluna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gaynon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Neglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith K.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210208","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2008.09.007","article-title":"Treatment of childhood acute lymphoblastic leukemia.","volume":"46","author":"Stanulla","year":"2009","journal-title":"Semin Hematol"},{"key":"R12-6-20210208","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2141.2006.06338.x","article-title":"Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemias.","volume":"135","author":"Uckun","year":"2006","journal-title":"Br J Haematol"},{"key":"R17-6-20210208","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11912-008-0070-3","article-title":"Relapsed acute lymphoblastic leukemia: current status and future opportunities.","volume":"10","author":"Harned","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"R18-6-20210208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"R20-6-20210208","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.V76.10.1908.bloodjournal76101908","article-title":"Regulation of human B-cell ontogeny (review).","volume":"76","author":"Uckun","year":"1990","journal-title":"Blood"},{"key":"R22-6-20210208","first-page":"3920","article-title":"Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells.","volume":"5","author":"Ghetie","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R23-6-20210208","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2141.1993.tb03329.x","article-title":"Immunotoxins for the treatment of leukemia (Review).","volume":"85","author":"Uckun","year":"1993","journal-title":"Br J Haematol"},{"key":"R33-6-20210208","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/biostatistics\/2.2.203","article-title":"Statistical properties of the traditional algorithm based designs for phase I cancer clinical trials.","volume":"2","author":"Lin","year":"2001","journal-title":"Biostatistics"},{"key":"R38-6-20210208","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium Study.","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"R40-6-20210208","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOP.0b013e3282f424b0","article-title":"The efficacy of rituximab in high-grade pediatric B-cell lymphomaleukemia: a review of available evidence.","volume":"20","author":"Attias","year":"2008","journal-title":"Curr Opin Pediatr"},{"key":"R42-6-20210208","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/CCO.0000000000000009","article-title":"Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.","volume":"25","author":"Hoelzer","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"R43-6-20210208","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3109\/10428194.2013.823493","article-title":"Novel targeted therapies in acute lymphoblastic leukemia.","volume":"55","author":"Portell","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R44-6-20210208","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/ejh.12408","article-title":"Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.","volume":"94","author":"Le Jeune","year":"2015","journal-title":"Eur J Haematol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0000000000000088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:57:44Z","timestamp":1621886264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-201509000-00006"}},"subtitle":["A Report From the Children\u2019s Oncology Group"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0000000000000088","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}